Of note, PRRX1 was amplified in ~ 10% (n = 36) of TCGA HCC tumour samples, but this amplification did not strikingly overlap with known mutated genes in HCC, i.e. TP53 or CTNNB1 (Fig. S1C). This evidence concerns the gene TP53 and neoplasm.